CVB homepage

Radiopharmaceutical manufacturing at a SOFIE Biosciences site

The Chicago-based imaging systems manufacturer will pay the purchase price in cash, acquiring the company from private equity firm Trilantic North America. 

Doctor patient

The AHA recognized more than 2,700 U.S. healthcare organizations for managing patients with high blood pressure, high cholesterol and/or type 2 diabetes. 

2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.

CMS just finalized major updates to its TAVR coverage policies. Could even more change be on the horizon? 

doctor with overweight patient who may be treated with TAVR or surgery

Orforglipron was linked to consistent weight loss in addition to reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein. In terms of safety, it was found to be noninferior to insulin glargine.

CardioMEMS Abbott heart failure

Heart failure patients with a CardioMEMS implant can now monitor their own pulmonary artery pressure readings and receive clinician feedback through a smartphone app.

weight loss scale overweight obese lose weight pounds

Some parents may be unsure about giving their children these medications. However, it can be worth it to avoid a lifetime of high blood pressure and other potentially harmful health conditions.

Innovation at work

For hospitals, health systems and physician groups, effective cardiovascular strategic planning is the foundation for better cardiovascular care delivery, stronger service line performance and sustainable program growth. This article offers a practical approach for cardiovascular leaders who want a service line strategy that is more than a document.

Sponsored by MedAxiom